Skip to content
naulon
Get started

No retraction, correction or concern found when last checked on Oct 24, 2026.

Targeting Immune Cells in the Tumor Microenvironment of HCC: New Opportunities and Challenges

Xiaopei Hao, Guangshun Sun, Yao Zhang and 5 more

Frontiers in Cell and Developmental Biology · 2021 · Review · CC BY

doi:10.3389/fcell.2021.775462

Abstract

Immune associated cells in the microenvironment have a significant impact on the development and progression of hepatocellular carcinoma (HCC) and have received more and more attention. Different types of immune-associated cells play different roles, including promoting/inhibiting HCC and several different types that are controversial. It is well known that immune escape of HCC has become a difficult problem in tumor therapy. Therefore, in recent years, a large number of studies have focused on the immune microenvironment of HCC, explored many mechanisms worth identifying tumor immunosuppression, and developed a variety of immunotherapy methods as targets, laying the foundation for the final victory in the fight against HCC. This paper reviews recent studies on the immune microenvironment of HCC that are more reliable and important, and provides a more comprehensive view of the investigation of the immune microenvironment of HCC and the development of more immunotherapeutic approaches based on the relevant summaries of different immune cells.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 24, 2026. Paragraph numbers are ours, so an answer can point at one.

Introduction

Hepatocellular carcinoma (HCC) is the most common type of liver cancer, accounting for the sixth most common type of cancer and the second leading cause of death among all cancers. Due to changes in environmental factors, immunization and people’s lifestyle, the incidence of HCC and HCC-related mortality are increasing all over the world. The latest research indicates that HCC accounts for approximately 85% of patients diagnosed with liver cirrhosis. Its 5-year survival rate is only 18%, second only to pancreatic cancer. With the improvement of the treatment level for HCC, a variety of treatment options such as liver transplantation, surgical removal, systemic therapy and liver targeted therapy are constantly enhanced and created. At present, only surgical treatment is considered as a potential radical treatment for HCC. But only 15% of HCC patients have the opportunity to have surgery, most patients are found in the advanced stage. Sorafenib is the only systemic medication approved by the FDA for advanced HCC. However, because of the overexpression of dihydropyrimine dehydrogenase, the multi-drug resistance gene MDR-1and p-glycoprotein gene products, HCC is regarded a chemotherapy-resistant tumour, and how to execute effective chemotherapy is still a major difficulty.

Seven essential characteristics of cancer have been identified as crosstalk between cells and immune cells, self-sufficiency of signals for growth, unrestricted replication potential, apoptosis avoidance, growth signals insensitivity and continuous angiogenesis and invasion/metastasis of tissue. Tumor cells, immune cells, stromal cells, endothelial cells, and cancer-related fibroblasts are all found in the tumour microenvironment (TME), according to current research. Malignant tumour cells can evade immune monitoring and kill, as well as impair the human body, via a range of intricate ways. Due to the limitations of traditional chemotherapy regimens in the treatment of HCC, a variety of immunotherapy methods for HCC have been developed. Immunotherapy mostly employs immune cells within or outside of the TME to specifically target and assault cancer cells, with the benefits of high specificity and low side effects. More crucially, thanks to advances in tools such as mass spectrometry and single-cell RNA sequencing, We can map immunological cells in TMEs at the single-cell level. We outline the significance of tumor-associated immune cells in the HCC tumour microenvironment and highlight their relevance in HCC cancer immunotherapy in this study.

The Immune Cells in TME

Tumor-associated immune cells are broadly classified into two types: tumor-promoting immune cells and tumor-antagonistic immune cells. At different stages of tumour formation, these two types of cells play different functions and impact each other (Figure 1). Because the significance of tumor-associated B cells in tumour growth is debatable, we shall introduce B cells additionally.

Effector T Cells

Current studies suggest that CD8+ cytotoxic T cells (CTLs) are the main lymphocytes that kill cancer cells. When CD8+ T cells recognize antibodies on DC, CD80−CD86 and CD70 ligands on DC connect to CD27 and CD28 receptors on CD8+ T cells, and CD8+ T cells are modified to become cytotoxic effector CD8+ T cells. Furthermore, CD4+ T cells can activate CD8+ T cells through CD40−CD40L interaction, and CD4+ T cells can produce IL-2 to enhance CD8+ T cell proliferation. CD4+ T cells are also important in the maturation of CD8+ T cells into memory cells. CTL kills target cells through granular exocytosis and apoptotic induction mediated by FasL ligand (FasL) in working state. CTL can also produce interferon- (IFN-) and tumour necrosis factor (TNF-) to cause cancer cell cytotoxicity. Activation and regulation of CTL requires signals from T cell receptors (TCR) and immune checkpoints. For example, cancer cells inhibit CTL activity through the expression of a ligand that binds to an inhibitory checkpoint, such as PD-L1. A significant number of studies have established the function of CD8+ T cells and CD4+ T cells in the formation and progression of HCC, including diagnosis/treatment/prognosis, and so on.

Chang et al. 's study confirmed that NanoMnSor improves the effectiveness of anti-PD-1 antibodies and whole-cell cancer vaccine immunotherapy by encouraging macrophage polarization to an immunostimulating M1 phenotype, decreasing hypoxica-induced tumor infiltration of tumor-associated macrophages, and raising the number of CD8 cytotoxic T cells in tumors, thereby reprogramming immunosuppressive TME. Xie et al. 's research proposed that PD-L1 overexpression is mostly triggered by pre-existing activated CD8 (+) cytotoxic T cells in the HCC environment, rather than being produced constitutively by tumor cells, and that it is a good prognostic factor for HCC. The frequency of circulating PD-1 (+) CD8 (+) T cells increases as the illness develops from LC to HCC. PD-1 expression was shown to be much higher in tumor-infiltrating CD8 (+) T cells. In vitro, CD8 (+) T cells promoted the production of PD-L1 on HCC cells in an IFN-dependent way, increasing CD8 (+) T cell death, whereas inhibiting PD-L1 reversed this effect.

Both in vitro restimulation and in vivo depletion studies have indicated that CD4+ and CD8+ lymphocytes contribute to anticancer activity. ASPH activation resulted in considerable production of antigen-specific CD4+ T cells in PBMC from healthy volunteers and HCC patients. Lack of recovered CD19+, CD3+, CD4+, and especially CD8+ T cells is associated with poor survival in patients. Zhou et al. ‘s revealed that antibodies against CD274 (PD-L1), LAG3, or TIM3 boost CD4+ and CD8+ TIL proliferation and cytokine secretion in response to polyclonal antigens or TAA stimulation. More research results on the effect of Effector T cells in HCC are summarized in Table 1. It is clear that Effector T cells play a critical role in the immunological milieu of HCC. Many studies have shown that targeting these cells is effective in patients with HCC.

NK Cells

NK cells are an essential anti-tumor immune cell that primarily mediates immune surveillance of malignancies. It performs a similar function as CD8+ T cells: NK cells regulate the killing response of tumor cells by releasing perforin and granulein, triggering apoptosis in target cells. In addition, to improve their anticancer activity, NK cells can produce proinflammatory cytokines and chemokines. Existing studies have confirmed the value of NK cells in the development, targeted therapy, prognosis of HCC. Sprinzl et al. 's research confirmed that Sorafenib can promote the pro-inflammatory response of tumor-associated macrophages in HCC, and then activate the anti-tumor NK cell response through the cytokine and NF-κB pathway. Senescence monitoring necessitates the recruitment and maturation of CCR2 myeloid cells, and CCR2 deficiency promotes HCC growth. Conversely, HCC cells suppress the maturation of recruited myeloid progenitors, which promotes mice HCC growth and worsens prognosis and survival in human HCC patients via NK cell inhibition. Kohga et al. 's revealed that natural killer (NK) cells had stronger cytolytic activity on ADAM9KD-HCC cells than on control cells, and that this cytotoxicity is enhanced by the MICA/B and NK group 2, D pathways. Sorafenib treatment resulted in a decrease in ADAM9 expression in HCC cells, an increase in membrane-bound MICA expression, and a decrease in the quantity of soluble MICA. Sorafenib increased HCC cell NK sensitivity by boosting the expression of membrane-bound MICA. Table 2 summarizes current research on NK cells in HCC, confirming the importance of NK cells in immune escape and anti-HCC therapy.

Dendritic cells

DC cells, as specialized antigen-presenting cells in the human body, can present antigens to T cells and produce costimulatory signals for T cell activation. According to the current study, mature DC cells can penetrate tumor cells and limit tumor incidence and progression. Under many severe conditions, this inhibition effect will be avoided by tumors through certain means. Therefore, targeting at DC cells, some studies have reported its role in the occurrence, development, immunotherapy, diagnosis and prognosis of HCC. For example, In mice, combining DC vaccination and PD-L1 inhibitor treatment can result in longer overall life, reduced tumor volume, and increased tumor cell apoptosis. As a new therapy method for HCC, combined treatment with DC vaccination and PD-L1 inhibitor may offer promising results. Ali et al. 's research clarified that the combination of PEI or RFTA with active antigen-specific immunotherapy using DCS is a promising approach to induce a sustained anti-tumor immune response aimed at reducing tumor recurrence and metastasis in patients with HCC. Table 3 summarizes the current role of DC cells in HCC.

M1-Polarized Macrophages

Another important type of immune cell in TME is macrophages derived from circulating monocytes, which can generally be divided into M2 polarization and M1 polarization (Figure 2). M1-polarized macrophages, for example, can create pro-inflammatory cytokines and reactive oxygen species/nitrogen to prevent the formation and progression of malignancies. There are limited investigations on the function of M1-polarized macrophages in HCC at the moment. Studies have shown that M1-polarized macrophages in the S3 subclass in HCC increased, and the prognosis was good. Memory B cells, Total B cells, M1 macrophages and T follicle helper cells, were linked with strong total immune cell infiltration into HCC, whereas resting mast cells, neutrophils, and NK cells were associated with poor infiltration. Table 4 summarizes the current role of M1-polarized macrophages in HCC.

Tumor-Promoting Immune Cells

In the immune microenvironment of HCC, some cells could promote the occurrence and development of HCC, and we will review them one by one.

Regulatory T cells(Tregs)

Tregs play a vital role in immunological homeostasis and immune self-tolerance, and they can express the CD4+ marker and the Foxp3 marker. Foxp3+ Treg acts as a switch for all levels of immune response, and its effects appear to be two-sided. First, Treg can inhibit harmful immune responses and thus inhibit the occurrence of autoimmune diseases. Second, Treg suppresses protective immune responses against invading pathogens or tumors, leading to further progression of the disease. How does Treg play a role in tumors, including how does Treg infiltrate and metastasize to tumor sites or how does Treg help tumors evade immune monitoring, has become a hot research topic in recent years. Many ideas have been put forward. Tregs were found in much higher numbers in HCC patients than in healthy controls. In addition, patients with high Treg(III) levels after TACE had a significantly lower progression-free survival than patients with low Treg(III) levels after TACE. Other studies have shown that tumor Treg upregulated the expression of the glucocorticoid-induced tumor necrosis factor receptor (GITR). Treatment with soluble GITR ligand (GITRL) reduced inhibition caused by activated tumor infiltrating Treg and restored CD4+ CD25-T cell proliferation and cytokine production.. In addition to that, the proportion of Tregs cells in HCC patients was significantly higher than that in healthy and cirrhosis controls, and was related to various clinical indicators of HCC patients. In HCC patients with BCLC stage C, the proportion of Treg cells was more pronounced than in BCLC stage B patients. One to 2 weeks after surgery, the fraction of Treg cells was much lower than before GSMS-TACE. Three to 5 weeks following surgery, the proportion of Treg cells continued to decline. Table 5 summarizes the most credible studies related to the role of Treg in HCC.

Myeloid-Derived Suppressor cells

MDSC is thought to be a cancer-promoting immune cell in the HCC tumor microenvironment and was discovered a decade ago. MDSC is divided into granulocyte or multinuclear MDSC(PMN MDSC) and mononuclear MDSC(M-MDSC). MDSCs enhance angiogenesis by producing vascular endothelial growth factor (VEGF), actuator 2 and MMP9. They can also cause cancer cells to migrate to endothelial cells and encourage metastasis. MDSC also suppresses T cell activity by secreting immunosuppressive cytokines, inducible nitric oxide synthase, and argininase. MDSCs can have a dual influence on immune cells via distinct methods. B cells, T cells, DCs and NK cells, are all inhibited by MDSCs. MDSCs, on the other hand, can stimulate Th17 cells, Tregs, and TAMs, as well as tumor angiogenesis and metastasis (Figure 3). There has been a great deal of research on the processes through which MDSC supports the advancement of HCC, and many therapeutic pathways have been developed for MDSC as a target of HCC. For example, myeloid-derived suppressor cells (MDSCs) are drawn to the tumor microenvironment by PIWIL1-overexpressed HCC cells. MDSCs consumption reduced the proliferation and growth of PIWIL1-overexpressed HCC tumors. Complement C3 stimulates HCC cell secretion via PIWIL1 and mediates the contact between HCC cells and MDSC via p38 MAPK activation in MD38, and then initiates the expression of immunosuppressive cytokine IL10. PIWIL1, which is expressed by tumor cells, could be a viable target for the development of new HCC treatments. Tumor-infiltrating LY6G MDSCs from orthotopic liver tumors treated with sorafenib dramatically increased CD4 T cells expressing IL-10 and TGF-and decreased CD8 T cell cytotoxicity. In vitro, IL-6 protects LY6G MDSC from sorafenib-induced cell death. Combining sorafenib and anti-IL-6 antibody or anti-LY6G antibody dramatically decreased the cell proportion of LY6G MDSCs in orthotopic liver tumors, synergistically boosted sorafenib’s therapeutic efficacy and increased T cell proliferation. Icaritin blocks MDSC production by blocking the attenuation of EMH, thereby inhibiting the immunosuppressive effect of the tumor, thereby triggering an anti-tumor immune response. Therefore, Icaritin can be used as a new adjuvant or even as an independent therapeutic agent for the effective treatment of HCC. In Table 6, we show the relevant role of MDSC in HCC immune microenvironment in recent years.

Cancer-Associated fibroblasts

CAF is not an immune cell, but it plays an important role in the tumor microenvironment, so we will introduce it in detail here. CAF exists as a prominent component of the tumor stroma between various inflammatory cells and components in the tumor microenvironment. As a result, CAF possesses functions that normal fibroblasts do not. A vast number of prior studies have demonstrated that CAF plays a critical function in changing the tumor microenvironment and driving the development of a variety of cancers. CAF is also significant in HCC. Many studies have revealed the great role of CAF in the pathogenesis, progression, prognosis, treatment and other aspects of HCC. CAF-derived cardioctonutrient-like cytokine 1 (CLCF1) has been found in studies to stimulate the release of TGF-β and CXCL6 in tumor cells, consequently increasing tumor stem cell development in HCC-TME. Other research have found that CCN2, EMA, and FAP expression may be involved in the activation of CAF in HCC, resulting in aggressive behavior. The substantial association between EMA-expressing tumor cells and FAP-expressing CAF, as well as their topographical proximity, suggests that there may be interplay between tumor epithelial and stromal cells in the HCC tumor microenvironment. Table 7 summarizes the current role of CAF in HCC.

M2-Polarized Macrophages

M2 polarized macrophages, as opposed to M1 polarized macrophages, have anti-inflammatory and pro-tumor actions (Figure 4). M2 macrophages are further differentiated into M2a, M2b, M2c, and M2d subsets. Th2 cytokines such as IL-13 and IL-4 can trigger macrophage transformation to the M2A phenotype, whereas TLR and immune complex activation induces M2B macrophages, the M2C subtype polarized by IL-10. Despite the fact that there have been few research on M2-polarized macrophages in HCC, the function of them in the occurrence and development of HCC has been confirmed. According to several studies, arsenite raises miR-15b levels and causes M2 polarization in THP-1 cells. Increased miR-15b in Evs transfer from arsenite-treated THP-1 (AS-THP-1) cells to HCC cells via miR-15b. By targeting LATS1, it can reduce Hippo pathway activation while still accelerating the invasion and metastasis of growing HCC cells. The potential therapeutic potential of M2 polarized macrophages has also been pointed out that Tumor cell-derived Wnt ligands induce M2-like polarization of TAM via traditional Wnt/-catenin signaling, resulting in tumor migration, development, immunosuppression and metastasis in HCC. We summarize the current relevant research progress in Table 8.

The Controversial Immune Cell Type in Cancer: B Cells

One type of immune cells that cannot be ignored in the HCC tumor microenvironment is B cells. According to the current relevant studies, it is not clear whether B cells are “good” or “bad”. Some studies have reported that B cells promote HCC, while others have reported the opposite effect. B cells, on the one hand, release cytokines that comport with CTL activity and serve as potent antigen-presenting cells (APCs). On the other hand, they may be tumorigenic due to the production of cytokines that attract MDSC and promote angiogenesis. Studies have shown that CCL20 derived from tumor cells interacts with CD19CD5 B cells overexpressed by CCR6 to promote the development of HCC, possibly through enhanced angiogenesis. Liu et al. 's study confirmed that Selective recruitment of CXCR3 (+) B cells Bridges the pro-inflammatory interleukin-17 response and the polarization of tumorigenic macrophages in the tumor environment, and blocking the migration or function of CXCR3+ B cells may help to overcome HCC. Therefore, B cells are involved in both the development and inhibition of HCC. Table 9 highlights the most recent reliable research on the involvement of B cells in HCC.

Conclusions and Perspectives

With the development of single-cell sequencing and other technologies, we have the opportunity to further explore TME. Immunotherapy, a new tumor treatment method, also has a better and broader application prospect. However, at present, it is still too early for immunotherapy to replace traditional chemotherapeutic therapy, and there is still a long way to go in the process of clinical application. However, immunotherapy can be regarded as a good alternative therapy for patients with chemotherapy resistance. As mentioned in this paper, immunotherapies for tumor suppressor related immune cells, such as effect DCs, as well as tumor promoting immune cells, such as MDSC/Treg, are being developed one after another.

Compared with traditional chemotherapy, immunotherapy has many advantages. For example, immunotherapy has fewer overall side effects than chemotherapy and, once effective, may lead to long-term survival and even clinical cure. In addition, immunotherapy can be used as an important anti-tumor adjuvant therapy in addition to chemotherapy, radiotherapy and surgery. Appropriate immunotherapy can kill the tiny residual tumor cells after chemotherapy or some tumor cells resistant to chemotherapy. Immunotherapy should be considered for patients who are intolerant to chemotherapy or have extensive metastasis and cannot undergo surgery, radiotherapy or chemotherapy.

At present, the mainstream immunotherapy mainly includes CAR T therapy/immune checkpoint inhibitor therapy (PD-1, PD-L1, etc.)/tumor vaccine. CAR-T is the T cells, biological engineering, when the cancer has an immune deficiency, immune surveillance, give play to the role of the case, through the biological engineering to determine the targets of leukemia, it specifically chimeric in T cells, to attack the leukemia cells, the effect is significant, but easy to appear “storm” cells, serious and even cause death. Immune checkpoint inhibitor therapy has the advantage of long-term survival and relatively small adverse reactions. This therapy activates tumor-specific immune cells in the body by removing or attenuating the negative regulatory factors of immunoreactive cells, but it is not suitable for all patients. The higher the mutation load, the better the treatment response. Therefore, biomarkers should be used to screen the dominant population. The most common predictive indicators of PD-1/PD-L1 immune checkpoint inhibitors are microsatellite instability, PD-L1 and tumor mutation load. The treatment of cancer vaccines is still incomplete.

Immunotherapy is not the end of tumor therapy; on the contrary, tumor immunotherapy represented by immune checkpoints has just opened a new chapter in tumor therapy. Combined with the basic and characteristics of immunotherapy, with the deepening of human understanding of tumors, tumors as a chronic disease that can be cured are no longer so far out of reach.

References 236

  1. 1.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  2. 2.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  3. 3.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  4. 4.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  5. 5.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  6. 6.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  7. 7.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  8. 8.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  9. 9.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  10. 10.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  11. 11.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  12. 12.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  13. 13.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  14. 14.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  15. 15.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  16. 16.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  17. 17.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  18. 18.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  19. 19.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  20. 20.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  21. 21.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  22. 22.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  23. 23.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  24. 24.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  25. 25.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  26. 26.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  27. 27.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  28. 28.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  29. 29.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  30. 30.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  31. 31.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  32. 32.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  33. 33.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  34. 34.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  35. 35.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  36. 36.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  37. 37.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  38. 38.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  39. 39.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  40. 40.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  41. 41.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  42. 42.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  43. 43.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  44. 44.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  45. 45.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  46. 46.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  47. 47.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  48. 48.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  49. 49.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  50. 50.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  51. 51.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  52. 52.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  53. 53.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  54. 54.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  55. 55.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  56. 56.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  57. 57.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  58. 58.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  59. 59.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  60. 60.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  61. 61.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  62. 62.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  63. 63.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  64. 64.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  65. 65.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  66. 66.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  67. 67.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  68. 68.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  69. 69.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  70. 70.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  71. 71.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  72. 72.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  73. 73.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  74. 74.
    Macrophages in Tumor Microenvironments and the Progression of Tumors · 2012
    No notice
  75. 75.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  76. 76.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  77. 77.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  78. 78.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  79. 79.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  80. 80.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  81. 81.
    High expression of IL-17 and IL-17RE associate with poor prognosis of hepatocellular carcinoma · 2013
    No notice
  82. 82.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  83. 83.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  84. 84.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  85. 85.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  86. 86.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  87. 87.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  88. 88.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  89. 89.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  90. 90.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  91. 91.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  92. 92.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  93. 93.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  94. 94.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  95. 95.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  96. 96.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  97. 97.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  98. 98.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  99. 99.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  100. 100.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  101. 101.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  102. 102.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  103. 103.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  104. 104.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  105. 105.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  106. 106.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  107. 107.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  108. 108.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  109. 109.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  110. 110.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  111. 111.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  112. 112.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  113. 113.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  114. 114.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  115. 115.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  116. 116.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  117. 117.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  118. 118.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  119. 119.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  120. 120.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  121. 121.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  122. 122.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  123. 123.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  124. 124.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  125. 125.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  126. 126.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  127. 127.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  128. 128.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  129. 129.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  130. 130.
    The long noncoding RNA lnc-EGFR stimulates T-regulatory cells differentiation thus promoting hepatocellular carcinoma immune evasion · 2017
    No notice
  131. 131.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  132. 132.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  133. 133.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  134. 134.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  135. 135.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  136. 136.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  137. 137.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  138. 138.
    Hypoxia inducible factor HIF-1 promotes myeloid-derived suppressor cells accumulation through ENTPD2/CD39L1 in hepatocellular carcinoma · 2017
    No notice
  139. 139.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  140. 140.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  141. 141.
    TAMeless traitors: macrophages in cancer progression and metastasis · 2017
    No notice
  142. 142.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  143. 143.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  144. 144.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  145. 145.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  146. 146.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  147. 147.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  148. 148.
    M2-polarized tumor-associated macrophages facilitated migration and epithelial-mesenchymal transition of HCC cells via the TLR4/STAT3 signaling pathway · 2018
    No notice
  149. 149.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  150. 150.
    Cancer-associated fibroblasts induce PDL1+ neutrophils through the IL6-STAT3 pathway that foster immune suppression in hepatocellular carcinoma · 2018
    No notice
  151. 151.
    Deviations of the immune cell landscape between healthy liver and hepatocellular carcinoma · 2018
    No notice
  152. 152.
    Carnitine palmitoyltransferase gene upregulation by linoleic acid induces CD4+ T cell apoptosis promoting HCC development · 2018
    No notice
  153. 153.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  154. 154.
    Crosstalk between hepatic tumor cells and macrophages via Wnt/β-catenin signaling promotes M2-like macrophage polarization and reinforces tumor malignant behaviors · 2018
    No notice
  155. 155.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  156. 156.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  157. 157.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  158. 158.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  159. 159.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  160. 160.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  161. 161.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  162. 162.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  163. 163.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  164. 164.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  165. 165.
    Tumor-derived exosomal HMGB1 fosters hepatocellular carcinoma immune evasion by promoting TIM-1+ regulatory B cell expansion · 2018
    No notice
  166. 166.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  167. 167.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  168. 168.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  169. 169.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  170. 170.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  171. 171.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  172. 172.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  173. 173.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  174. 174.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  175. 175.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  176. 176.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  177. 177.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  178. 178.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  179. 179.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  180. 180.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  181. 181.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  182. 182.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  183. 183.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  184. 184.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  185. 185.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  186. 186.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  187. 187.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  188. 188.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  189. 189.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  190. 190.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  191. 191.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  192. 192.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  193. 193.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  194. 194.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  195. 195.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  196. 196.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  197. 197.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  198. 198.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  199. 199.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  200. 200.
    PD1Hi CD8+ T cells correlate with exhausted signature and poor clinical outcome in hepatocellular carcinoma · 2019
    No notice
  201. 201.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  202. 202.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  203. 203.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  204. 204.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  205. 205.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  206. 206.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  207. 207.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  208. 208.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  209. 209.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  210. 210.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  211. 211.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  212. 212.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  213. 213.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  214. 214.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  215. 215.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  216. 216.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  217. 217.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  218. 218.
    Efficacy of anti-CD147 chimeric antigen receptors targeting hepatocellular carcinoma · 2020
    No notice
  219. 219.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  220. 220.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  221. 221.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  222. 222.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  223. 223.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  224. 224.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  225. 225.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  226. 226.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  227. 227.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  228. 228.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  229. 229.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  230. 230.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  231. 231.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  232. 232.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  233. 233.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  234. 234.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  235. 235.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  236. 236.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

Cited by papers we hold 1

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.